![](/img/cover-not-exists.png)
785OLutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
Hofman, M.S., Sandhu, S., Eu, P., Price, J., Akhurst, T., Iravani, A., Kong, G., Ravi-Kumar, A., Williams, S., Thang, S-P., Murphy, D., Scalzo, M., Hicks, R.J., Violet, J.Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx370.002
Date:
September, 2017
File:
PDF, 49 KB
english, 2017